Biosyngen

About:

Biosyngen is scientific research company.

Top Investors: SCI Group

Description:

Biosyngen is developing multiple T-cell immunotherapies with the aim to address a wide range of malignancies. BioSyngen Group is dedicated in the clinical and commercial transfer of innovative immune-cell therapy technologies and products. It develops immune cell therapies for aggaressive cancers.

Total Funding Amount:

500M CNY

Headquarters Location:

Singapore, Central Region, Singapore

Founded Date:

2016-01-01

Contact Email:

info(AT)biosg.com

Founders:

Victor Lietao

Number of Employees:

11-50

Last Funding Date:

2021-10-21

IPO Status:

Private

Industries: